– UK, London – Avacta Group plc (LON: AVCT), a clinical-stage biopharmaceutical company today announced the appointment of Dr. Christina Coughlin (M.D., Ph.D.) to its Board as a Non-Executive Director with immediate effect.
“I am delighted that Christina will be joining the Board of Avacta. Christina will bring a wealth of clinical and drug development experience and expertise which will be invaluable as we progress our pipeline of proprietary Affimer and pre|CISION programmes in the clinic. I look forward to working with her again on the Avacta Board.” said Board Chairman, Dr. Eliot Forster.
About Dr. Christina Coughlin
Dr. Christina Coughlin is the CEO of CytoImmune Therapeutics, Inc., a clinical-stage biotechnology company, focused on the development and commercialization of novel cancer immunotherapy products utilizing engineered allogeneic natural killer cells to stimulate the patient’s immune system and eliminate cancer cells. Dr. Coughlin has a broad background in biotechnology and global pharmaceuticals, with comprehensive drug development experience spanning programs in pre-Investigational New Drug studies through late-stage trials and regulatory approval filings, and a track record of building drug development teams in global companies.
Dr. Coughlin previously served as CMO to Rubius Therapeutics, Inc., where she led the clinical development, translational medicine, and regulatory efforts for the company’s programs emerging from its allogeneic red cell therapy platform. Before Rubius, Dr. Coughlin was with Tmunity Therapeutics, Inc., where she served as CMO and was responsible for the development of autologous CAR-T and TCR-T cellular therapies.
Dr. Coughlin has held other leadership roles in the pharmaceutical and biotechnology fields in her career, including CMO at Immunocore, heading the development of the soluble TCR platform, and Oncology Asset Team Leader at Pfizer. Dr. Coughlin received her M.D. and Ph.D. from the University of Pennsylvania and completed fellowships in Haematology and Oncology at the Children’s Hospital of Philadelphia and in the Translational Research Group under the direction of Carl June, M.D., at the University of Pennsylvania.
Dr. Christina Coughlin, said: “I find the Affimer and pre|CISION platforms to be highly innovative in the oncology field. I look forward to joining the Board and working with my new colleagues and the Avacta management team to develop novel therapies that will improve the lives of patients suffering from cancer.”
For more information: https://www.avacta.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
